Comparison of whole-body PET/CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically M0 squamous cell carcinoma of the head and neck

Journal of Nuclear Medicine

Volumn 50, Issue 8, 2009, Pages 1205-1213

  Rodrigues, Rosana S ^a   Bozza, Fernando A ^b   Christian, Paul E ^c   Hoffman, John M ^d   Butterfield, Regan I ^c   Christensen, Carl R ^d   Heilbrun, Marta ^d   Wiggins III, Richard H ^d   Hunt, Jason P ^d   Bentz, Brandon G ^d   Hitchcock, Ying J ^d   Morton, Kathryn A ^d  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Computed tomography; Head and neck cancer; Positron emission tomography; Squamous cell carcinoma; Tumor staging

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CERVICAL LYMPH NODE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FEMALE; HEAD AND NECK CARCINOMA; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MALE; NECK DISSECTION; PREDICTION AND FORECASTING; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; TUMOR LOCALIZATION; WHOLE BODY CT; WHOLE BODY PET;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CONTRAST MEDIA; HEAD AND NECK NEOPLASMS; HUMANS; IMAGE ENHANCEMENT; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 68249135113     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.062075     Document Type: Article

References (29)

1. Schoder H, Yeung HW, Gonen M, Kraus D, Larson SM. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology. 2004; 231:65-72.
2. Di Martino E, Nowak B, Hassan HA, et al. Diagnosis and staging of head and neck cancer: a comparison of modern imaging modalities (positron emission tomography, computed tomography, color-coded duplex sonography) with panendoscopic and histopathologic findings. Arch Otolaryngol Head Neck Surg. 2000;126: 1457-1461.
3. 18F- fluorodeoxyglucose positron emission tomography in patients with head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93:202-207.
4. Goerres GW, Schmid DT, Gratz KW, von Schulthess GK, Eyrich GK. Impact of whole body positron emission tomography on initial staging and therapy in patients with squamous cell carcinoma of the oral cavity. Oral Oncol. 2003; 39:547-551.
5. 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck. 2004;26:890-896.
6. Goerres GW, Schmid DT, Bandhauer F, et al. Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2004;130:105-109.
7. Goshen E, Yahalom R, Talmi YP, Rotenberg G, Oksman Y, Zwas ST. The role of gamma-PET in the evaluation of patients with recurrent squamous cell cancer of the head and neck. Int J Oral Maxillofac Surg. 2005;34:386-390.
8. Schwartz DL, Rajendran J, Yueh B, et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg. 2004;130: 1361-1367.
9. Agarwal V, Branstetter BF IV, Johnson JT. Indications for PET/CT in the head and neck. Otolaryngol Clin North Am. 2008;41:23-49.
10. 18F]fluorodeoxyglucose positron emission tomography compared with physical examination and conventional imaging modalities. J Oral Maxillofac Surg. 2003;61:1022-1029.
11. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. J Nucl Med. 2005;46:1136-1143.
12. 18F- fluorodeoxyglucose-positron emission tomography and computed tomography as a primary screening method for detecting second primary cancers and distant metastases in patients with head and neck cancer. Ann Oncol. 2007;18:1698-1703.
13. Branstetter BF IV, Blodgett TM, Zimmer LA, et al. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology. 2005;235:580-586.
14. 18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope. 2007;117:1173-1179.
15. Gordin A, Daitzchman M, Doweck I, et al. Fluorodeoxyglucose-positron emission tomography/computed tomography imaging in patients with carcinoma of the larynx: diagnostic accuracy and impact on clinical management. Laryngoscope. 2006;116:273-278.
16. Gordin A, Golz A, Keidar Z, Daitzchman M, Bar-Shalom R, Israel O. The role of FDG-PET/CT imaging in head and neck malignant conditions: impact on diagnostic accuracy and patient care. Otolaryngol Head Neck Surg. 2007;137: 130-137.
17. Scott AM, Gunawardana DH, Bartholomeusz D, Ramshaw JE, Lin P. PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective study. J Nucl Med. 2008; 49:1593-1600.
18. Yamamoto Y, Wong TZ, Turkington TG, Hawk TC, Coleman RE. Head and neck cancer: dedicated FDG PET/CT protocol for detection - phantom and initial clinical studies. Radiology. 2007;244:263-272.
19. Hain SF. Positron emission tomography in cancer of the head and neck. Br J Oral Maxillofac Surg. 2005;43:1-6.
20. De Bondt RB, Nelemans PJ, Hofman PA, et al. Detection of lymph node metastases in head and neck cancer: a meta-analysis comparing US, USgFNAC, CT and MR imaging. Eur J Radiol. 2007;64:266-272.
21. 18F-FDG PET imaging for the differentiation between malignant and benign lesions. Clin Radiol. 2008;63:756-764.
22. Zytoon AA, Murakami K, El-Kholy MR, El-Shorbagy E. Dual time point FDG-PET/CT imaging: potential tool for diagnosis of breast cancer. Clin Radiol. 2008;63:1213-1227.
23. Hustinx R, Smith RJ, Benard F, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med. 1999;26:1345-1348.
24. 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412-1417.
25. Veit-Haibach P, Luczak C, Wanke I, et al. TNM staging with FDG-PET/CT in patients with primary head and neck cancer. Eur J Nucl Med Mol Imaging. 2007;34:1953-1962.
26. AAssar OS, Fischbein NJ, Caputo GR, et al. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. Radiology. 1999;210:177-181.
27. 18F)fluorodeoxyglucose (FDG) in head and neck tumours. Acta Otolaryngol. 2007;127:186-193.
28. Nabili V, Zaia B, Blackwell KE, Head CS, Grabski K, Sercarz JA. Positron emission tomography: poor sensitivity for occult tonsillar cancer. Am J Otolaryngol. 2007;28:153-157.
29. Ishimori T, Patel PV, Wahl RL. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med. 2005;46:752-757.